**Figure S3.** Network diagrams

*Figure 3a*: MTX-naïve population American College of Rheumatology Responses network of evidence

X:\ScHARR\TAG_General\General\RA Update Nov 2016\Publication\Network\ACR Popn 1 Main_network diagram.tiff

*Figure 3b*: MTX-naïve population European League Against Rheumatism Responses network of evidence

X:\ScHARR\TAG_General\General\RA Update Nov 2016\Publication\Network\EULAR Popn 1 Main_network diagram.tiff

*Figure 3c*: csDMARD-experienced population American College of Rheumatology Responses network of evidence

X:\ScHARR\TAG_General\General\RA Update Nov 2016\Publication\Network\ACR Popn 23 Main Biosim_network diagram.tiff

*Figure 3d*: csDMARD-experienced population European League Against Rheumatism responses network of evidence

X:\ScHARR\TAG_General\General\RA Update Nov 2016\Publication\Network\EULAR Popn 23 Main Biosim_network diagram.tiff

+ represents combination therapy; ACR=American College of Rheumatology; ABT=abatacept; ADA=adalimumab; Biosim=biosimilar; CTZ=certolizumab pegol; ETN=etanercept; EULAR=European League Against Rheumatism; GOL=golimumab; Grouped biologics=one of ADA, ETN or IFX ; IFX=infliximab; Int csDMARDs= intensive csDMARDs (two or more csDMARDs); MP=methylprednisolone; PBO=placebo; SU = step-up treatment; TCZ=tocilizumab